| SATURDAY,
MARCH 24, 2001 |
08:30-10:10
 |
CASE
PRESENTATIONS: CONTROVERSIES IN GLAUCOMA
Chairpersons:
E. Higginbotham, USA
C.S. Migdal, UK |
Hall
A |
08:30-08:50
|
DIFFERENTIATING
GLAUCOMA FROM OHT - DO WE HAVE THE TOOLS?
Moderator: R.N. Weinreb, USA
PRO
J.M. Liebmann, USA
CON
I. Goldberg, Australia |
Hall
A |
08:55-
9:15
|
INITIAL
DIAGNOSIS AS ADVANCED GLAUCOMA - WHAT THERAPY DO YOU CHOOSE?
Moderator: M. Aquino, Philippines
MEDICAL VIEW
J.I. Katz, USA
LASER AND SURGICAL VIEW
R.A. Hitchings, UK |
Hall
A |
09:20-09:40
|
GLAUCOMA
PROGRESSION DESPITE SINGLE DIGIT IOP - WHAT TO DO?
Moderator: D.A. Lee, USA |
Hall
A |
| 09:20 |
Discussion |
|
| 09:25 |
1ST
OPINION
A. Bechetoille, France |
|
| 09:28 |
2ND
OPINION
L.E. Pillunat, Germany |
|
| 09:31 |
|
|
| 09:34 |
Discussion |
|
09:45-10:05
|
PROGRESSIVE
GLAUCOMA DESPITE MAXIMALLY TOLERATED MEDICAL THERAPY - WHAT TO DO NEXT?
Moderator: J. Brandt, USA
LASER VIEW
J.A. Alvarado, USA
TRAB VIEW
P. Rojanapongpun, Thailand
NPFS VIEW
A. Mermoud, Switzerland |
Hall
A |
10:30-12:00
|
THE
IMPORTANCE OF LOWERING IOP
Sponsored by Pharmacia & Upjohn
Chairperson:
M.B. Wax, USA |
Hall
A |
| 10.30 |
CLINICAL DECISIONS BASED ON
THE RELATIONSHIP BETWEEN INTRAOCULAR PRESSURE AND GLAUCOMATOUS OPTIC
NEUROPATHY: WHAT WE HAVE LEARNED FROM EPIDEMIOLOGIC STUDIES
K. Singh, USA |
|
| 10.43 |
THE
IMPORTANCE OF UNIFORM CIRCADIAN IOP CONTROL
S. Asrani, USA |
|
| 10.56 |
COMPARISON
OF THE EFFECT OF TIMOLOL, LATANOPROST, DORZOLAMIDE, BRIMONIDINE, AND
FIXED COMBINATION OF TIMOLOL AND DORZOLAMIDE ON CIRCADIAN IOP IN
PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION
N. Orzalesi, Italy |
|
| 11.09 |
COMPARISION
OF THE EFFICACY AND SAFETY OF LATANOPROST WITH BRIMONIDINE IN PATIENTS
WITH OPEN-ANGLE GLAUCOMA AND OCULAR HYPERTENSION
H. Uusitalo,
Finland
|
|
| 11.22 |
AN
EFFICACY AND SAFETY EVALUATION OF REPLACEMENT OF DUAL THERAPY WITH
LATANOPROST MONOTHERAPY IN GLAUCOMA PATIENTS
L.E. Pillunat, Germany |
|
| 11.35 |
OCULAR
HYPOTENSIVE EFFECT OF LATANOPROST AS COMPARED WITH ISOPROPYL UNOPROSTONE
T. Yamamoto, Japan |
|
| 11.48 |
Discussion |
|
| 12:00 |
Lunch
Break |
|
13:00-14:30
|
NEW
DEVELOPMENTS IN THE TREATMENT OF POAG
Sponsored by Alcon
Chairperson:
P.A. Netland, USA |
Hall
A |
| 13:00 |
A
STUDY OF THE EFFICACY AND SAFETY AZOPT (BRINZOLAMIDE 1% OPHTHALMIC
SUSPENSION) AND DORZOLAMIDE 2% OPHTHALMIC SOLUTION (TRUSOPT) AS
ADJUNCTIVE THERAPY TO TIMOLOL 0.5%
P. Wishart, UK |
|
| 13:15 |
PRIMARY
THERAPY STUDIES WITH BRINZOLAMIDE
J. Thygesen, Denmark |
|
| 13:30 |
EFFACACY
AND COMFORT OF SWITCHING PATIENTS FROM DORZOLAMIDE TO BRINZOLAMIDE
H.S. Barnebey, USA |
|
| 13:45 |
DOSE
RESPONSE STUDIES WITH TRAVATAN -TM A NEW PROSTAGLANDIN ANALOG IN
PATIENTS WITH OCULAR HYPERTENSION OR OPEN-ANGLE GLAUCOMA
T.R. Dean, USA |
|
| 14:00 |
THE
SAFETY AND IOP LOWERING-EFFICACY OF A NEW TOPICAL OCULAR PROSTAGLANDIN
ANALOGUE, TRAVOPROST (0.0015% AND 0.004%), COMPARED TO TIMOLOL 0.5%, IN
A NINE-MONTH MULTICENTER STUDY
S.I. Orgul, Switzerland |
|
| 14:15 |
COMPARISON
OF THE SAFETY AND EFFICACY OF TRAVOPROST, LATANOPROST AND TIMOLOL IN
PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
P. Netland, USA |
|
14:30-15:40
|
MEDICAL
THERAPY I
Chairperson:
J.D. Brandt, USA
Co-Moderators:
M. Lusky, Israel
T. Yamamoto, Japan |
Hall
A |
| 14:30 |
LONG-TERM
USE OF BRIMONIDINE 0.2% IN THE MANAGEMENT OF OCULAR HYPERTENSION AND
GLAUCOMA: FOUR YEARS OF EXPERIENCE
S. Melamed, Israel |
|
| 14:38 |
6-MONTH
COMPARISON OF AGN 192024 QD AND BID WITH TIMOLOL BID IN PATIENTS WITH
ELEVATED IOP.
I. Goldberg, Australia |
|
| 14:46 |
EFFICACY
OF ISOPROPYL UNOPROSTONE AND TIMOLOL MALEATE IN CHRONIC OPEN ANGLE
GLAUCOMA OR OCULAR HYPERTENSION. A COMPARATIVE DOUBLE MASKED RANDOMIZED
CLINICAL TRIAL
C.R. Moura, F.B. Duarte, C. Rocha, V. Villaca, V.P. Costa, P.A.A. Mello,
A. Paranhos-Jr, Brazil |
|
| 14:54 |
OPTIC
NERVE HEAD PERFUSION AND ENDOTHELIN-1 IN PRIMARY OPEN ANGLE GLAUCOMA
PATIENTS ON UNOPROSTONE AND LATANOPROST
K.G. Schmidt, UK |
|
| 15:02 |
COMPARATIVE
STUDY OF AZOPT AND TRUSOPT INFLUENCE ON IOP
A. Egorov, Russia |
|
| 15:10 |
CLINICAL
STUDY OF NYOLOL GEL 0/1% IN THE TREATMEN OF PATIENTS WITH OPEN ANGLE
GLAUCOMA
D. Kazakova, Bulgaria |
|
| 15:18 |
A
NEW FIXED COMBINATION FOR THE MEDICAL MANAGEMENT OF GLAUCOMA: OVERVIEW
OF PHASE III RESULTS FROM THE UNITED STATES
E. Higginbotham, USA |
|
| 15:26 |
A
COMPARISON OF THE EFFICACY, SAFETY, AND QUALITY-OF-LIFE EFFECTS OF
BRIMONIDINE/LATANOPROST VERSUS TIMOLOL/LATANOPROST DUAL THERAPY
L. Cantor and T. Walters, USA |
|
| 15:34 |
discussion |
|
16:00-18:00
|
PROGRESS
IN TREATMENT MODALITIES FOR GLAUCOMA
Sponsored by Allergan
Chaiperson:
R. Weinreb, USA
Moderator:
J. Schuman, USA |
Hall
A |
| 16:00 |
INTRODUCTION
R. Weinreb, USA |
|
| 16:05 |
LUMIGAN
(AGN 192024): STUDIES ON A PHARMACOLOGICALLY NOVEL OCULAR HYPOTENSIVE
AGENT
A.H. Krauss, J. Chen, F. Woodward, USA |
|
| 16:20 |
CLINICAL
OVERVIEW OF LUMIGAN
I. Goldberg, Australia |
|
| 16:35 |
CLINICAL
EVALUATIONS OF AGN 192024 (LUMIGAN)
L.B. Cantor, USA |
|
| 16:50 |
QUESTIONS
AND ANSWERS
R. Weinreb, USA |
|
| 17:00 |
WHAT
DAMAGES THE OPTIC NERVE IN GLAUCOMA?
R.N. Weinreb, USA |
|
| 17:15 |
THE
ROLE OF PHARMACEUTICAL AGENTS IN NEUROPROTECTION
L. Wheeler, USA |
|
| 17:30 |
HOW
WE MEASURE DAMAGE AND INJURY IN GLAUCOMA
J.S. Schuman, USA |
|
| 17:40 |
THE
ROLE OF ALPHA-2 IN GLAUCOMA
S. Melamed, Israel |
|
| 17:50 |
QUESTIONS
AND ANSWERS
R.N. Weinreb, USA |
|
14:30-15:30
|
IMAGING
COURSE HANDS ON
Co Sponsored by Heidelberg; Humphrey; Laser Diagnostic; Talia Technology
Moderator:
J. Airaksinen, Finland |
Hall
B |
| 15:30 |
Coffee
Break |
|
SCIENTIFIC PROGRAM
